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Inhibition of COX-2 counteracts the effects of diuretics in rat. the activity of the renin system [3, 4]. This effect becomes
Background. It is well established that the diuretic- and renin- more evident in states of diuresis and saluresis induced
stimulated effects of loop diuretics can be attenuated by non- by diuretics or in renal salt and water wasting disordersselective cyclooxygenase inhibitors. Since it is yet unclear which
such as the Bartter disease [5, 6]. A variety of species,of the isoforms of cyclooxygenases, COX-1 and COX-2, is rele-
including humans and rat, express both cyclooxygenasevant in this context, our study aimed to determine the effects
of selective COX-2 inhibition on the renal effects of the loop isoforms, namely COX-1 and COX-2, in the kidney [7, 8].
diuretic furosemide, as well as the diuretic hydrochlorothiazide, COX-1 is mainly localized in the inner medulla [9],
which acts on the distal tubule. whereas COX-2 is found in the thick ascending limb ofMethod. Male Sprague-Dawley rats were treated with furo-
Henle including the macula densa region as well as insemide (12 mg/day subcutaneously by osmotic pump) or hydro-
collecting ducts [9, 10]. Which isoform of cyclooxygen-chlorothiazide (30 mg/kg body weight/day orally by gavage). In
addition, parallel groups received rofecoxib (1 to 10 mg/kg body ases is of major relevance for the generation of prosta-
weight/day) for selective inhibition of COX-2. Controls were glandins involved in renal salt and water excretion is yet
treated with vehicle. unknown. As to the stimulation of the renin system byResults. Induction of COX-2 mRNA expression due to furo-
loop diuretics, there is first evidence for COX-2– rathersemide was paralleled by increased renal excretion of prosta-
than COX-1–derived prostanoids that mediate the stimu-noids. Also, hydrochlorothiazide led to a rise in prostanoid
excretion. Rofecoxib blunted the diuretic-induced increase in lation of renin secretion [11]. Such an involvement of
prostanoid excretion, thus confirming an effective blockade COX-2–derived prostanoids is in good accordance with
of COX-2. Moreover, the COX-2 inhibitor rofecoxib dose- reports that macula densa cells, which are closely neigh-dependently attenuated diuresis and saluresis, as well as the
bored to the renin-producing juxtaglomerular cells, ex-stimulation of the renin system induced by furosemide. Fur-
press COX-2 [12] and that selective COX-2 inhibitorsthermore, rofecoxib completely reversed diuresis and saluresis
and prevented the increase of plasma renin activity induced inhibit the stimulation of the renin system by different
by hydrochlorothiazide. maneuvers [13–15]. Moreover, the expression of COX-2
Conclusions. These findings suggest that COX-2–derived in the thick ascending limb of Henle, including the mac-prostanoids are of major relevance in modulating the renal
ula densa region, is up-regulated by loop diuretics [16]effects of diuretics. COX-2 inhibitors might be valuable drugs
and in Bartter disease [17]. These findings prompted usto treat salt and water wasting during Bartter and Gitelman
diseases. to investigate a possible mediator function of COX-2–
derived prostanoids for renal salt and water excretion in
states of diuresis resembling genetic renal disorders such
It is well established that prostaglandins can exert ma- as Bartter and Gitelman diseases. Bartter disease results
jor influence on renal salt and water handling as well as from insufficient salt reabsorption in the thick ascending
on the activity of the renin system in the kidney [1, 2]. limb of Henle, which can be caused by defects of the
As a consequence, inhibition of prostanoid formation apical Na, K, 2Cl-cotransporter NKCC-2, the apical po-
reduces renal salt and water excretion and attenuates tassium channel ROMK, or the basolateral chloride chan-
nel ClC-Kb [18]. We aimed to mimic the Bartter disease
in the rat by chronic infusion of the loop diuretic furose-
Key words: salt and water wasting, Bartter disease, Gitelman disease,
mide, which blocks NKCC-2 activity in the thick ascendingloop diuretics, furosemide, hydrochlorothiazide, renin system, prosta-
glandins, saluresis, urinary excretion. limb of Henle. Gitelman disease results from an insuffi-
cient salt reabsorption in the convoluted part of the distalReceived for publication December 15, 2000
tubule by a defect of the apical NaCl cotransporter (NCC)and in revised form March 28, 2001
Accepted for publication June 5, 2001 [18]. Gitelman disease was mimicked by chronic adminis-
tration of hydrochlorothiazide, which specifically blocks 2001 by the International Society of Nephrology
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NCC in the kidney [19]. To allow compensation of salt which were frozen in liquid nitrogen and stored at80C
until extraction of total RNA.and water loss, the animals had free access to salt water
All animal experiments were conducted in accordanceand free water. To assess the possible renal effects of
with the NIH Guide for the Care and Use of LaboratoryCOX-2–derived prostanoids in these animal models, the
Animals.rats were treated with the selective COX-2 inhibitor
rofecoxib [20]. We found that the COX-2 inhibitor mark-
Extraction of RNAedly attenuated salt and water excretion induced by both
Total cortical RNA was extracted according to thediuretics. In parallel, the COX-2 inhibitor attenuated the
acid-guanidinium-phenol-chloroform protocol describedwell-known stimulation of renin secretion by the diuretics.
in detail by Chomczynski and Sacchi [21].If these findings obtained in rats can be transferred to
RNA pellets were dissolved in diethylpyrocarbonate-humans, then inhibition of COX-2 activity could be a
treated water. The yield of RNA was quantified by spec-viable therapy for alleviating the symptoms of renal salt
troscopy at 260 nm. Samples were aliquoted and storedwasting diseases.
at 80C until further processing.
Ribonuclease protection assays for renin, COX-2,METHODS
and -actinIn vivo experiments
Renin, COX-2 and -actin mRNA levels were mea-For all animal experiments, male Sprague-Dawley rats
sured by RNase protection assay basically as describedweighing 150 to 175 g were used. They received standard
previously [5, 22, 23]. In brief, after linearization and puri-rat chow (0.5% NaCl wt/wt; Trouw Nutrition, Burgheim,
fication with phenol/chloroform, the plasmids yielded ra-Germany) with free access to tap water and a solution
diolabeled antisense cRNA transcripts by incubationcontaining 0.9% sodium chloride and 0.1% potassium
with SP6 polymerase (Promega, Mannheim, Germany)chloride. They were housed individually in metabolic
and -32 P-GTP (Amersham Pharmacia Biotech, Frei-cages with a 12-hour light/dark cycle. Urine collections
burg, Germany) according to the Promega riboprobe inwere performed for 24 hours during the last two days.
vitro transcription protocol; 40 g total RNA and 40 gControl animals (N  6) were treated with vehicle or
t-RNA (negative control) were hybridized with 500,000rofecoxib (10 mg/kg body weight/day in 2 single doses
cpm of the cRNA probes at 60C overnight. Thereafter,
by gavage). For the experiments with furosemide and
RNase A/T1 (RT/30 min) and proteinase K (37C for 30
hydrochlorothiazide, the control groups (N  3 to 4)
min) were used for digestion. After phenol/chloroform
were treated with vehicle, one group with the diuretic and extraction and ethanol precipitation, protected frag-
vehicle, and one group with the diuretic and rofecoxib ments were separated on an 8% polyacrylamide gel. The
(N 10). Therefore, furosemide was chronically infused gel was dried for two hours. Bands were quantitated in a
subcutaneously for seven days via an osmotic pump with Phosphoimager (Instant Imager 2024; Packard, Meriden,
a dose of 12 mg/day (model 2ML1, ALZET Osmotic CT, USA). Autoradiography was performed at 80C
Pumps, Durect Corporation, Cupertino, CA, USA). The for one day.
osmotic pumps were placed subcutaneously under gen-
eral anesthesia with methohexital 50 mg/kg body wt (Lilly, Determination of plasma renin activity
Bad Homburg, Germany). Controls received saline-filled Plasma renin activity (PRA) was determined by a com-
osmotic pumps. Hydrochlorothiazide (Novartis, Wehr, mercially available radioimmunoassay (DiaSorin, Du¨s-
Germany) was dissolved in propylenglycol (Bufa Phar- seldorf, Germany).
maceutical Products, Uttgeest, Holland); for COX-2 in-
hibition, the commercially available oral suspension of Urinary electrolytes and osmolality
rofecoxib was used (MSD, Haar, Germany). All drugs Urinary sodium and potassium concentrations were
except furosemide were administered for five days with measured by flame photometry using a low temperature,
a total daily dose of 30 mg/kg body weight for hydrochlo- single-channel emission flame photometer (PFP7; Jen-
rothiazide and 10 mg/kg body weight for rofecoxib. They way, Dunmow, Essex, UK). Excretion rates for sodium
were applied orally by gavage twice per day. and potassium were calculated.
Furthermore, for the dose response experiments, furo- Urinary osmolality was measured by depression of the
semide-treated rats received a daily dose of either vehicle freezing point using a semi-micro osmometer (Knauer,
or rofecocxib at 1, 3, or 10 mg/kg body weight (N  3). Berlin, Germany).
The animals were killed by decapitation, and blood
Measurement of urinary excreted prostaglandinswas collected from the carotid arteries in ethylenedi-
aminetetraacetic acid (EDTA) pretreated tubes. Kid- By gas chromatography and mass spectroscopy, the con-
centrations of the renally excreted prostanoids, namelyneys were removed rapidly for dissection of the cortices,
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Fig. 1. COX-2 mRNA after seven days of treatment with furosemide or
hydrochlorothiazide (5 days). Parallel groups were additionally treated
with vehicle or rofecoxib (10 mg/kg body weight/day) for 5 days. Symbols
are: ( ) control () diuretic; ( ) additional rofecoxib. Data are means
SEM, and the asterisk marks significant differences with P  0.05.
of the PGE2 group (PGE2, PGE-M), the PGF1 group
(6kPGF1, d6kPGF1), and the thromboxane group (TXB2,
2,3dTXB2, 11dhTXB2), were measured as described in
detail previously [24].
Statistical analysis
Differences between the groups were analyzed by
analysis of variance with multiple comparisons. P values
less than 0.05 were considered significant.
RESULTS
Effect of diuretics and rofecoxib on renal COX-2
expression and prostaglandin excretion
The loop diuretic furosemide led to a significant in-
Fig. 2. Urinary prostaglandin excretion after seven days of treatmentcrease of renocortical COX-2 mRNA expression (Fig.
with furosemide or hydrochlorothiazide (5 days). (A) PGE2 	 metabo-1). In parallel with the induction of COX-2, renal excre- lite; (B) PGF1 	 metabolites; (C) TXB2 	 metabolites. Parallel groups
were additionally treated with vehicle or rofecoxib (10 mg/kg bodytion of prostaglandins was stimulated by furosemide two-
weight/day) for 5 days. Symbols are: ( ) control () diuretic; ( )to fivefold compared with controls (Fig. 2).
additional rofecoxib. Data are means  SEM, and the asterisk marks
Inhibition of COX-2 with rofecoxib led to a rather significant differences with P  0.05.
enhanced stimulation of COX-2 mRNA expression dur-
ing treatment with furosemide (Fig.1). In contrast, the
furosemide-induced stimulation of prostanoid excretion
Additional rofecoxib administration during hydro-was completely reversed by rofecoxib, thus confirming
chlorothiazide treatment caused an increase in COX-2the effective inhibition of COX-2 (Fig. 2). To decrease
mRNA expression (Fig. 1) and blunted the stimulationthe furosemide-induced prostanoid excretion signifi-
of urinary prostanoid excretion. Prostanoid excretioncantly, rofecoxib doses higher than 3 mg/kg body weight
was suppressed partially below control levels (Fig. 2).were necessary (Fig. 3)
Hydrochlorothiazide, a blocker of NaCl cotransport
Effect of rofecoxib on diuretic-induced salt andin the convoluted part of the distal tubule, had no effect
water excretionon basal COX-2 mRNA expression (Fig. 1). However,
Furosemide infusion increased urine production ap-there was an increase in renal prostanoid excretion of
the PGF1 and TXB2 groups (Fig. 2). proximately fivefold, sodium excretion about 3.5-fold,
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Fig. 3. Urinary prostaglandin excretion after seven days of furosemide
infusion and additional treatment with vehicle or rofecoxib (1 to 10
mg/kg body weight/day) for five days. (A) PGE2 	 metabolites; (B)
PGF1 	 metabolites; (C) TXB2 	 metabolites. Dotted lines represent
values of vehicle-treated controls; data are means  SEM, and the
Fig. 4. Urine volume (A), urine sodium excretion (B), and urine potas-asterisk marks significant difference compared to control with P 0.05.
sium excretion (C ) after seven days of treatment with furosemide or
hydrochlorothiazide (5 days). Parallel groups were additionally treated
with vehicle or rofecoxib (10 mg/kg body weight/day) for five days.
Symbols are: ( ) control () diuretic; ( ) additional rofecoxib. Data
are means  SEM, and the asterisk marks significant differences with
and potassium excretion by 15% (Fig. 4). When the rats P  0.05.
were treated with furosemide in combination with the
COX-2 blocker rofecoxib (10 mg/kg body weight/day),
the urine, sodium, and potassium outputs were signifi- 6), the half-maximal effect on salt and water retention
cantly reduced when compared with furosemide alone. occurred with a dose between 1 to 3 mg/kg per day of
Relative to untreated controls, urine output increased rofecoxib.
2.5-fold and sodium excretion increased twofold, whereas Hydrochlorothiazide increased urine and sodium out-
potassium excretion remained normal with the combina- put by about 50% and 20%, respectively, and did not
tion of furosemide and rofecoxib (Fig. 4). Furosemide change potassium excretion (Fig. 4). This increase of urine
treatment also led to a marked fall of urine osmolality and sodium output was absent if the rats received hydro-
(Fig. 5). This effect of furosemide was not changed by chlorothiazide in combination with rofecoxib (Fig. 4).
rofecoxib. In further considering the dose dependency Hydrochlorothiazide moderately lowered urine osmolal-
ity, an effect that was reversed by rofecoxib (Fig. 5).for rofecoxib on the diuretic effect of furosemide (Fig.
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Fig. 5. Urine osmolality after seven days of treatment with furosemide
or hydrochlorothiazide (5 days). Parallel groups were additionally treated
with vehicle or rofecoxib (10 mg/kg body weight/day) for five days.
Symbols are: ( ) control () diuretic; ( ) additional rofecoxib. Data
are means  SEM, and the asterisk marks significant differences with
P  0.05.
Fig. 7. Plasma renin activity (PRA) (A) and renin mRNA (B) after
seven days of treatment with furosemide or hydrochlorothiazide (5 days).
Parallel groups were additionally treated with vehicle or rofecoxib (10
mg/kg body weight/day) for five days. Symbols are: ( ) control ()
diuretic; ( ) additional rofecoxib. Data are means  SEM, and the
asterisk marks significant differences with P 0.05; ns is not significant.
Effect of rofecoxib on diuretics induced
stimulation of renin
Furosemide infusion also led to a sixfold increase in
plasma renin activity and to a 2.5-fold increase in renal
renin mRNA levels (Fig. 7). Rofecoxib significantly at-
tenuated this stimulation of renin secretion and renin
gene expression, but did not reduce these parameters to
basal control levels. The effect of rofecoxib to attenuate
the furosemide-induced stimulation of the renin system
required doses greater than 3 mg/kg/day (Fig. 8).
Hydrochlorothiazide treatment increased plasma re-
nin activity twofold without changing renal renin mRNA
levels. Rofecoxib prevented the increase of PRA by hy-
drochlorothiazide (Fig. 7).
Fig. 6. Urine volume (A) and urine sodium excretion (B) after seven DISCUSSIONdays of furosemide infusion and additional treatment with vehicle or
rofecoxib (1 to 10 mg/kg body weight/day) for five days. Dotted lines Since it is well known that inhibition of prostanoid
represent values of vehicle-treated controls. Data are means  SEM, formation attenuates the salt and water loss that occursand the asterisk marks significant difference compared to control with
P  0.05. during treatment with loop diuretics or in the case of
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hancement of renal prostaglandin output and stimulation
of renin secretion by furosemide.
Our data now show that the highly selective COX-2
inhibitor, rofecoxib, in fact markedly attenuates the stim-
ulation of the renin system by furosemide, suggesting
that the up-regulation of COX-2 in the macula densa
and consequent up-regulation of COX-2–derived prosta-
glandins mediate the stimulation of renin secretion and
of renin synthesis induced by loop diuretics. A similar
conclusion was reached previously using the less selec-
tive COX-2 inhibitor, meloxicam, in humans [11].
In parallel, the COX-2 blocker markedly attenuated
diuresis and saluresis by furosemide, suggesting that inhi-
bition of COX-2–derived prostaglandins mainly accounts
for the salt- and water-sparing effects of nonselective
COX inhibitors during treatment with loop diuretics or
during Bartter disease [5, 6, 11]. This finding is in accor-
dance with a preliminary report that the COX-2 inhibitor
nimesulide attenuates salt and water loss in Bartter pa-
tients (abstract; Nu¨sing et al, Eur J Clin Pharmacol
55:A10, 1999).
Since both inhibition of saluresis/diuresis and of the
renin system depend on the dose of rofecoxib, these
parameters could serve as possible markers for adjusting
the therapeutic dose in patients with Bartter disease.
Fig. 8. PRA (A) and renin mRNA (B) after seven days of furosemide
The well-known fall of urine osmolality induced byinfusion and additional treatment with vehicle or rofecoxib (1 to 10
inhibition of salt transport in the TALH was not influ-mg/kg body weight/day) for five days. Dotted lines represent values of
vehicle-treated controls. Data are means SEM, and the asterisk marks enced by COX-2 inhibition. This is in accordance with an
significant difference compared with control with P  0.05.
action of prostaglandins in the distal nephron, and indi-
cates that COX-2–derived prostanoids are not involved
in the breakdown of the corticomedullary osmolality gra-
dient induced by loop diuretics [28]. Considering theBartter disease, this study aimed to determine the role
of cyclooxygenase-2 in this context. This question was enhancement of COX-2 expression and renal prostaglan-
din production by impaired salt transport in the TALH,interesting because the kidneys of different species, in-
cluding humans and rats, express both the COX-1 and it is tempting to speculate that the diuretic and natriuretic
actions of furosemide comprise two effects, namely, aCOX-2 isoforms [7, 8]. The role of COX-2–derived
prostanoids has gained much interest during the last direct COX-2–independent inhibition of salt transport
at the level of TALH and an increased formation ofyears, since COX-2 activity appears to be required for
normal renal development [25] and for the stimulation COX-2–derived prostaglandins leading to inhibition of
salt transport at the level of the collecting duct, whichof the renin system under a variety of conditions [13–15].
COX-2 is evidently expressed in the cortical thick as- is consistent with the expression of COX-2 in the cortical
thick ascending limb and the macula densa [9].cending limb of Henle (TALH), including the macula
densa region and in the collecting duct system [9, 10]. Our findings also show that the diuretic and saluretic
effects of hydrochlorothiazide, which inhibits the NCC inThe expression of COX-2 in the TALH and the macula
densa, moreover, is subject to regulation in the way that the distal tubule [18], are completely reversed by COX-2
inhibition. Compared with furosemide, however, hydro-it is up-regulated during a low-salt diet, renal hypoperfu-
sion, and treatment with angiotensin II antagonists, and chlorothiazide leads to a weaker enhancement of renal
prostaglandin excretion. Furthermore, no stimulation ofdown-regulated in states of salt overload [9, 10, 14, 15,
22, 26]. It has been suggested that the chloride concentra- cortical COX-2 expression by hydrochlorothiazide was
found. We assume that inhibition of NCC does not stimu-tion in the TALH cells is an important regulator of
COX-2 expression [27]. In line with this hypothesis, we late the formation of renal COX-2–derived prostanoids.
The antidiuretic and antisaluretic effects of rofecoxibpreviously reported that inhibition of salt transport in
the TALH by the loop diuretic furosemide up-regulates during hydrochlorothiazide treatment may result from
either preventing the normal action of COX-2–derivedCOX-2 expression in the TALH and in the macula densa
[16], thus providing a possible explanation for the en- prostanoids or from a reversed stimulation of systemic
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